医学
特应性皮炎
临床试验
销售授权
肾脏疾病
内科学
授权
重症监护医学
皮肤病科
生物信息学
生物
计算机安全
计算机科学
出处
期刊:Drugs
[Springer Nature]
日期:2021-10-21
卷期号:81 (16): 1937-1944
被引量:28
标识
DOI:10.1007/s40265-021-01619-6
摘要
Difelikefalin (Korsuva™) is a synthetic peptide agonist of the kappa opioid receptor being developed by Cara Therapeutics for the treatment of pruritus. In August 2021, intravenous difelikefalin was approved in the USA for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing haemodialysis. Intravenous difelikefalin has also been evaluated for CKD-associated pruritus in patients undergoing haemodialysis in various other countries, with Marketing Authorization Application under regulatory review in the EU and a phase III trial ongoing in Japan. Clinical studies of an oral formulation of difelikefalin have also been completed or are underway in pruritus indications, including pruritus associated with atopic dermatitis, notalgia paraesthetica or primary biliary cholangitis. This article summarizes the milestones in the development of difelikefalin leading to this first approval for CKD-associated pruritus in adults undergoing haemodialysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI